CAS: 82-88-2; 2-Methyl-9-Phenyl-1,3,4,9-Tetrahydroindeno[2,1-C]Pyridine

结构式图片

MSDS等安全信息

    上下游产品

    CAS号71839-14-0 2,3-dihydro-2-m... | CAS号60295-97-8 2-methyl-9-phen... | CAS号64-17-5 乙醇

    合成工艺路线路线简述

      📜Alkaline Earth Salt Of/the/ Methylsulfuric Acid置于sodium Hydroxide,氯化亚砜体系中,化学反应生成 苯茚胺
      参考文献:Pyridindenes And Process For Their Manufacture
      标题:Pyridindenes And Process For Their Manufacture

      海关参考信息

      专利信息


      专利号:US-4310535-A
      优先权日:1976-11-30
      标题:Combination of drugs and a method for the selective control of the immune reactions evoked in a host by the administration of antigens
      发明人:PIERPAOLI WALTER
      权利人:PIERPAOLI WALTER
      摘要:The invention concerns a new composition or combination of drugs effective to selectively control the immune reactions which are evoked in a host by the administration of antigens. It comprises active components capable of simultaneously blocking the alpha -adrenergic receptors of the cells for catecholamine, blocking the dopaminergic receptors of the cells and increasing the synthesis of serotonin. Preferred drug combinations according to the invention contain in association phentolamine, haloperidol, L-5-hydroxy-tryptophane and possibly dopamine.

      专利号:WO-2023075715-A1
      优先权日:2021-10-26
      标题 :A pharmaceutical formulation including leukotriene receptor antagonists and/or leukotriene synthesis inhibitors combined with non-steroidal anti-inflammatory drugs (nsaids)
      发明人:OYTUN FARUK; CAN EFE
      权利人:VSY BIYOTEKNOLOJI VE ILAC SANAYI ANONIM SIRKETI
      摘要:This invention is related to a pharmaceutical formulation including Leukotriene receptor antagonists and/or Leukotriene synthesis inhibitors combined with non-steroidal anti-inflammatory drugs (NSAIDs) and antihistamines in ocular diseases and in inflammatory and allergic diseases for systemic and topical use. The objective of this invention is to create a novel formulation to be effective as much as steroids while having significantly less side effects for long-term use in treating ocular diseases, inflammatory and allergic diseases. In other words our aim is to achieve the inhibition of pro-inflammatory mediators (prostaglandins, thromboxane, histamine and leukotrienes) as much as steroids do with a safer combination.

      专利号:US-7354923-B2
      优先权日:2001-08-10
      标 题 :Piperazine melanocortin-specific compounds
      发明人:SHARMA SHUBH D; SHI YI-QUN; WU ZHIJUN; RAJPUROHIT RAMESH
      权利人:PALATIN TECHNOLOGIES INC
      摘要:Melanocortin receptor-specific piperazine or ketopiperazine compounds having the structure: n nand stereoisomer and pharmaceutically acceptable salts thereof, where X is CH 2 or Câ•?O, R 1 , R 2 , and R 3 are as described in the specification, preferably where R 3 is a D-amino acid with at least one substituted or unsubstituted phenyl or naphthyl aromatic ring, and where R 3 optionally further includes an amine capping group, a second amino acid residue or a second amino acid residue with an amine capping group, which compounds are agonists, antagonists or mixed agonists and antagonists at one or more melanocortin receptors, and having utility in the treatment of melanocortin receptor-related disorders and conditions. Methods of synthesis of compounds of structure (I), pharmaceutical compositions containing a compound of structure (I) and methods relating to the use thereof are also disclosed.

      专利号:WO-2005102340-A1
      优先权日:2003-05-30
      标题 :Piperazine melanocortin-specific compounds
      发明人:SHARMA SHUBH D; SHI YI-QUN; WU ZHIJUN; RAJPUROHIT RAMESH
      权利人:PALATIN TECHNOLOGIES INC; SHARMA SHUBH D; SHI YI-QUN; WU ZHIJUN; RAJPUROHIT RAMESH
      摘要:Melanocortin receptor-specific piperazine or ketopiperazine compounds having the structure (I); and stereoisomer and pharmaceutically acceptable salts thereof, where X is CH2 or C=O, R1, R2, and R3 are as described in the specification, preferably where R3 is a D-amino acid with at least one substituted or unsubstituted phenyl or naphthyl aromatic ring, and where R3 optionally further includes an amine capping group, a second amino acid residue or a second amino acid residue with an amine capping group, which compounds are agonists, antagonists or mixed agonists and antagonists at one or more melanocortin receptors, and having utility in the treatment of melanocortin receptor-related disorders and conditions. Methods of synthesis of compounds of structure (I), pharmaceutical compositions containing a compound of structure (I) and methods relating to the use thereof are also disclosed.

      专利号:US-2013030282-A1
      优先权日:2011-07-18
      标题:Synthesis and characterization of near ir fluorescent magnetic and non-magnetic albumin nanoparticles for biomedical applications
      发明人:MARGEL SHLOMO; COHEN SARIT; SALKMON ENAV COREM; PELLACH MICHAL
      权利人:UNIV BAR ILAN; MARGEL SHLOMO; COHEN SARIT; SALKMON ENAV COREM; PELLACH MICHAL
      摘要:The present invention discloses Near Infrared (NIR) fluorescent albumin nanoparticles having a structure selected from a core structure or a core-shell structure. Also disclosed are a process of preparing these NIR fluorescent albumin nanoparticles, and a method of in vivo detection of pathologies, in particular cancer pathology, by using administering these NIR fluorescent albumin nanoparticles to a patient.

      专利号:US-2007148246-A1
      优先权日:2005-08-11
      标题:Nucleic Acid-Based Matrixes
      发明人:LUO DAN; LI YOUGEN
      权利人:LUO DAN; LI YOUGEN
      摘要:Various nucleic acid-based matrixes are provided, comprising nucleic acid monomers as building blocks, as well as nucleic acids encoding proteins, so as to produce novel biomaterials. Methods of utilizing such biomaterials include delivery of biologically active agents, cell and tissue culture, and cell-free protein synthesis.

      供应商参考报价(招募中)

      品牌试剂参考报价(招募中)

      📌 第三方产品分析报告

      ✅ COA系统入驻 | 共享模式

      主要参考文献


      1: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–. Phenindamine. 2018 Oct 31. 90(6 Pt 1):953-61. doi: 10.1016/0091-6749(92)90468-h. 40(1):83-4. doi: 10.1111/j.2042-7158.1988.tb05164.x. 69(3):342-4. doi: 10.1002/jps.2600690324. 46(1):65-72. doi: 10.1007/BF00421551. 28(17):3056-63. doi: 10.1002/elps.200700222. 74(2):394-8. doi: 10.3181/00379727-74-17919. 1147(2):261-9. doi: 10.1016/j.chroma.2007.02.054. Epub 2007 Feb 22. 188(2):271-83. 13(4):311-8.

      合成参考文献


      摘要:Archives Internationales de Pharmacodynamie et de Therapie., 188(271), 1970 []
      摘要:P. B. Marshall. Brit. J. Pharmacol. 10, 270 (1955).
      摘要:S72 | NTUPHTW | Pharmaceutically Active Substances from National Taiwan University | DOI:10.5281/zenodo.3955664
      摘要:OKA MJ, PAASONEN MK. The effect of chlor-trimeton and thephorin on the circulatory and blood sugar changes produced by adrenaline. Ann Med Exp Biol Fenn. 1953;31(4):422–31.
      📝 需求与反馈
      尽可能描述清楚需求与问题信息
      ×

      通知